AtriCure Inc.
| NASDAQ: ATRC | Healthcare / Medical Devices & Instruments / USA |
| 40.83 | +2.85 | +7.50% | Vol 808.98K | 1Y Perf -39.93% |
| Mar 24th, 2023 16:00 DELAYED |
| BID | 16.36 | ASK | 48.15 | ||
| Open | 37.69 | Previous Close | 37.98 | ||
| Pre-Market | - | After-Market | 40.83 | ||
| - - | - -% |
| Target Price | 59.33 | Analyst Rating | Strong Buy 1.43 | |
| Potential % | 45.31 | Finscreener Ranking | ★★★ 49.85 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★+ 52.54 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★+ 49.22 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 23.07 | Earnings Rating | Sell | |
| Market Cap | 1.90B | Earnings Date | 2nd May 2023 | |
| Alpha | 0.01 | Standard Deviation | 0.12 | |
| Beta | 1.15 |
Today's Price Range 37.5241.06 | 52W Range 32.5168.58 | 5 Year PE Ratio Range -45.30-24.00 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | 4.16% | ||
| 1 Month | 2.56% | ||
| 3 Months | -6.55% | ||
| 6 Months | 5.89% | ||
| 1 Year | -39.93% | ||
| 3 Years | 38.69% | ||
| 5 Years | 103.74% | ||
| 10 Years | 410.38% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -2.37 | |||
ROE last 12 Months | -11.94 | |||
ROA (5Y Avg) | -1.03 | |||
ROA last 12 Months | -9.38 | |||
ROC (5Y Avg) | -8.89 | |||
ROC last 12 Months | -9.89 | |||
Return on invested Capital Q | -2.32 | |||
Return on invested Capital Y | -2.33 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 2.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -37.50 | ||||
| 4.72 | ||||
| 8.42 | ||||
| 255.30 | ||||
| -60.90 | ||||
| -0.48 | ||||
| 12.12 | ||||
| 9.68 | ||||
| 2.08B | ||||
| Forward PE | -47.22 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.80 | ||||
| 3.70 | ||||
| 0.14 | ||||
| 0.17 | ||||
| -11.40 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 74.70 | ||||
| -16.30 | ||||
| -12.60 | ||||
| -16.60 | ||||
| -17.45 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 242.35M | ||||
| 5.21 | ||||
| 8.11 | ||||
| 9.99 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2022 | -0.18 | -0.09 | 50.00 |
| Q03 2022 | -0.25 | -0.27 | -8.00 |
| Q02 2022 | -0.30 | -0.32 | -6.67 |
| Q01 2022 | -0.33 | -0.33 | 0.00 |
| Q04 2021 | -0.26 | -0.30 | -15.38 |
| Q03 2021 | -0.28 | -0.23 | 17.86 |
| Q02 2021 | -0.30 | -0.30 | 0.00 |
| Q01 2021 | -0.38 | -0.32 | 15.79 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.18 | -5.88 | Negative |
| 12/2022 FY | -1.10 | -0.92 | Negative |
| 3/2023 QR | -0.26 | 7.14 | Positive |
| 12/2023 FY | -0.83 | 7.78 | Positive |
| Next Report Date | 2nd May 2023 |
| Estimated EPS Next Report | -0.34 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 808.98K |
| Shares Outstanding | 46.57K |
| Shares Float | 45.22M |
| Trades Count | 10.64K |
| Dollar Volume | 32.13M |
| Avg. Volume | 365.27K |
| Avg. Weekly Volume | 412.92K |
| Avg. Monthly Volume | 356.42K |
| Avg. Quarterly Volume | 326.47K |
AtriCure Inc. (NASDAQ: ATRC) stock closed at 40.83 per share at the end of the most recent trading day (a 7.5% change compared to the prior day closing price) with a volume of 808.98K shares and market capitalization of 1.90B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 730 people. AtriCure Inc. CEO is Michael H. Carrel.
The one-year performance of AtriCure Inc. stock is -39.93%, while year-to-date (YTD) performance is -8%. ATRC stock has a five-year performance of 103.74%. Its 52-week range is between 32.51 and 68.58, which gives ATRC stock a 52-week price range ratio of 23.07%
AtriCure Inc. currently has a PE ratio of -37.50, a price-to-book (PB) ratio of 4.72, a price-to-sale (PS) ratio of 8.42, a price to cashflow ratio of 255.30, a PEG ratio of 2.32, a ROA of -9.38%, a ROC of -9.89% and a ROE of -11.94%. The company’s profit margin is -17.45%, its EBITDA margin is -12.60%, and its revenue ttm is $242.35 Million , which makes it $5.21 revenue per share.
Of the last four earnings reports from AtriCure Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. AtriCure Inc.’s next earnings report date is 02nd May 2023.
The consensus rating of Wall Street analysts for AtriCure Inc. is Strong Buy (1.43), with a target price of $59.33, which is +45.31% compared to the current price. The earnings rating for AtriCure Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AtriCure Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AtriCure Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.83, ATR14 : 1.78, CCI20 : 109.52, Chaikin Money Flow : 0.00, MACD : -0.52, Money Flow Index : 59.54, ROC : 7.45, RSI : 55.30, STOCH (14,3) : 96.08, STOCH RSI : 1.00, UO : 49.89, Williams %R : -3.92), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AtriCure Inc. in the last 12-months were: Mark A. Collar (Option Excercise at a value of $93 000), Robert S. White (Option Excercise at a value of $296 800), Tonya Austin (Sold 3 485 shares of value $154 104 ), Vinayak Doraiswamy (Sold 4 983 shares of value $229 168 )
AtriCure Inc.
AtriCure Inc an atrial fibrillation solutions company that provides products, professional education, and support for clinical science to reduce the economic and social burden of atrial fibrillation. Its products line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offer a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
CEO: Michael H. Carrel
Telephone: +1 513 755-4100
Address: 7555 Innovation Way, Mason 45040, OH, US
Number of employees: 730
